<?xml version="1.0" encoding="UTF-8"?>
<p>Recent 
 <italic>in vitro</italic> reports demonstrated the potential efficacy of ivermectin against SAR-COV-2. 5000-fold reduced the viral load (in 2-h post-infection with SARS-CoV-2 Vero-hSLAM cells) after 48 h of single ivermectin treatment (5 μM) [
 <xref rid="B126" ref-type="bibr">126</xref>]. An observational study showed the survival benefits of using single ivermectin dose (150 mg/kg) after initiating mechanical ventilation in critically ill SAR-COV-2 patients. Patients who received ivermectin showed better survival, shorter hospital stay and intensive care unit length [
 <xref rid="B127" ref-type="bibr">127</xref>]. A recent study from Italy is suggesting a synergistic effect of combining hydroxychloroquine with ivermectin against SAR-COV-2. The study is hypothesizing that the two drugs have no serious interactions and can be safely studied against SAR-COV-2 [
 <xref rid="B128" ref-type="bibr">128</xref>].
</p>
